MEK inhibitor 162
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MEK inhibitor 162, covering 2021-04-20 to 2021-04-20. Get the full timeline:
Most recent: Clinical Trial Update: MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy [Phase 1, Phase 2]